HIV PREVENTION, DIAGNOSIS, TREATMENT AND CARE FOR KEY POPULATIONS

Similar documents
HIV PREVENTION, DIAGNOSIS, TREATMENT AND CARE FOR KEY POPULATIONS

GUIDANCE FOR SAMPLING ART CLINICS IN COUNTRIES COMBINING SURVEILLANCE OF PRE-TREATMENT HIV DRUG RESISTANCE AND ACQUIRED HIV DRUG RESISTANCE AT 12 AND

Latent tuberculosis infection

WHO REPORT ON THE GLOBAL TOBACCO EPIDEMIC,

Summary report on the WHO-EM/WRH/104/E

BEST PRACTICES IN MICROPLANNING FOR CHILDREN OUT OF THE HOUSEHOLD: AN EXAMPLE FROM NORTHERN NIGERIA

Raising tobacco taxes in Bangladesh in FY : An opportunity for development

WHO IMPLEMENTATION TOOL FOR PRE-EXPOSURE PROPHYLAXIS (PrEP) OF HIV INFECTION

WEB ANNEX I. REPORT ON COST-EFFECTIVENESS OF IMPLEMENTING AN INDETERMINATE RANGE FOR EARLY INFANT DIAGNOSIS OF HIV

Latent tuberculosis infection

BEST PRACTICES FOR PLANNING A VACCINATION CAMPAIGN FOR AN ENTIRE POPULATION

Sex Work in Sub-Saharan Africa : Opportunities and Challenges

preventing suicide Regional strategy on

FAST-TRACK COMMITMENTS TO END AIDS BY 2030

HIV/AIDS Prevention, Treatment and Care among Injecting Drug Users and in Prisons

HIV AND PEOPLE WHO INJECT DRUGS

NATIONAL AIDS PROGRAMME MANAGEMENT A SET OF TRAINING MODULES

Technical Guidance Note for Global Fund HIV Proposals

Summary report on the WHO-EM/CSR/124/E

World Health Organization. A Sustainable Health Sector

hiv/aids Programme meeting report March 2012, Siem Reap, Cambodia Executive Summary

END HIV/AIDS BY 2030 HIV/AIDS: FRAMEWORK FOR ACTION IN THE WHO AFRICAN REGION,

Checklist for assessing the gender responsiveness of sexual and reproductive health policies. Pilot document for adaptation to national contexts

IFMSA Policy Statement Ending AIDS by 2030

STI and HIV Prevention and Care among Sex Workers

Program to control HIV/AIDS

UNAIDS 2013 AIDS by the numbers

END HEPATITIS BY 2030 PREVENTION, CARE AND TREATMENT OF VIRAL HEPATITIS IN THE AFRICAN REGION: FRAMEWORK FOR ACTION,

TECHNICAL UPDATE HIV DRUG RESISTANCE HIV DRUG RESISTANCE SURVEILLANCE GUIDANCE: 2015 UPDATE

Multidrug-/ rifampicinresistant. (MDR/RR-TB): Update 2017

Investing for Impact Prioritizing HIV Programs for GF Concept Notes. Lisa Nelson, WHO Iris Semini, UNAIDS

Towards universal access

4. Timing of post-abortion contraception

Regional Response Plan for TB-HIV

Harm Reduction in Nigeria

WHO/NMH/TFI/11.3. Warning about the dangers of tobacco. Executive summary. fresh and alive

Copyright 2011 Joint United Nations Programme on HIV/AIDS (UNAIDS) All rights reserved ISBN

State of InequalIty. Reproductive, maternal, newborn and child health. executi ve S ummary

MONITORING HEALTH INEQUALITY

Sexual and Reproductive Health and HIV. Dr. Rita Kabra Training course in Sexual and Reproductive Health Research Geneva 2012

DECLARATION ON ACCELERATION OF HIV PREVENTION EFFORTS IN THE AFRICAN REGION

Diabetes. Halt the diabetes epidemic

TOWARDS UNIVERSAL ACCESS

90% 90% 90% 30% 10% 5% 70% 90% 95% WHY HIV SELF-TESTING? PLHIV diagnosed PLHIV undiagnosed

2016 United Nations Political Declaration on Ending AIDS sets world on the Fast-Track to end the epidemic by 2030

Strategic use of antiretroviral drugs to prevent HIV transmission

GLOBAL AIDS MONITORING REPORT

BUDGET AND RESOURCE ALLOCATION MATRIX

Six things you need to know

UNAIDS 99.1E (English original, March 1999) This document, presenting a speech given at the United Nations General Assembly Special Session on Drugs,

THE GAP REPORT 2014 PRisOnERs

Linkages between Sexual and Reproductive Health and HIV

Antiretroviral therapy for adults and adolescents KEY MESSAGES. HIV/AIDS Department BACKGROUND

Version for the Silent Procedure 29 April Agenda item January Hepatitis

UNAIDS 2018 THE YOUTH BULGE AND HIV

WHO Library Cataloguing-in-Publication Data. World health statistics 2011.

Module 3 Determining programme priorities and approaches

FPA Sri Lanka Policy: Men and Sexual and Reproductive Health

Which Scale Up Strategies/Programmatic Mixes are most Cost-Effective? Iris Semini UNAIDS May 2018

MONITORING THE BUILDING BLOCKS OF HEALTH SYSTEMS: A HANDBOOK OF INDICATORS AND THEIR MEASUREMENT STRATEGIES

Prevention and control of Hepatitis B and C among vulnerable groups Estonia: People who use drugs

Translating Science to end HIV in Latin America and the Caribbean

KENYA AIDS STRATEGIC FRAMEWORK 2014/ /2019

LEADING THE HEALTH SECTOR RESPONSE TO HIV/AIDS

HIV Prevention in Young People: Current Context, Opportunities and Challenges Dr. Susan Kasedde Senior Specialist, HIV Prevention UNICEF, NY

26 28 May 2010, Almaty, Kazkhstan. Nina Kerimi UNODC Regional Project Coordinator 1

HIV/AIDS Programme. Strengthening health services to fight HIV/AIDS GUIDANCE ON PROVIDER-INITIATED HIV TESTING AND COUNSELLING IN HEALTH FACILITIES

UPDATE UNAIDS 2016 DATE 2016

HIV in key populations: the global context and agenda

Operational Guidance on Sharing Seasonal Influenza viruses with WHO Collaborating Centres (CCs) under the Global Influenza Surveillance and Response

Prevention of HIV in infants and young children

ViiV Healthcare s Position on Prevention in HIV

On the Fast-Track to end AIDS. HIV & AIDS in the Post 2015 Development Agenda

ASEAN Declaration of Commitment on HIV and AIDS: Fast-Tracking and Sustaining HIV and AIDS Responses To End the AIDS Epidemic by 2030

No adolescent living with HIV left behind: a coalition for action

Thresia Sebastian MD, MPH University of Colorado, Denver Global Health Disasters Course October 2016

Module 9 Strategic information

ART for prevention the task ahead

Children and AIDS Fourth Stocktaking Report 2009

High Level Regional Consultation for Policy Makers to Enhance Leadership in Planning the National HIV & AIDS Response. HIV Prevention (PM1S4)

Country progress report - Bangladesh. Global AIDS Monitoring 2017

The Comprehensive Package: The simple truth about our response to drug related HIV. Dr. Monica Beg, Signe Rotberga UNODC

CUTANEOUS LEISHMANIASIS

Groups of young people in Uganda that need to be targeted with HIV interventions

Goal of this chapter. 6.1 Introduction Good practices for linkage to care General care for people living with HIV 84

HIV Prevention Prioritization & Implementation Brief: Gombe State

HIV Prevention, Care and Treatment Services in Prisons of North-Eastern States of India

GOOD PHARMACOPOEIAL PRACTICES

GLOBAL DRUG POLICY AND THE HIV/IDU EPIDEMIC IN EASTERN EUROPE AND CENTRAL ASIA. The critical need to scale up opioid substitution therapy

People left behind: Sex workers

Global health sector strategies on HIV, viral hepatitis and sexually transmitted infections ( )

TRANSITION TO NEW ANTIRETROVIRALS IN HIV PROGRAMMES

HIV Prevention Prioritization & Implementation Brief: Kaduna State

Economic and Social Council

Executive Board of the United Nations Development Programme, the United Nations Population Fund and the United Nations Office for Project Services

HIV in Zambia MINISTRY OF HEALTH. Dr Albert Mwango, BScHB, MBChB, MPH National Antiretroviral Program Coordinator,

Public health dimension of the world drug problem

Gender inequality and genderbased

Scaling up priority HIV/AIDS interventions in the health sector

Positive Health, Dignity, and Prevention in Botswana

Transcription:

POLICY BRIEF HIV PREVENTION, DIAGNOSIS, TREATMENT AND CARE FOR KEY POPULATIONS CONSOLIDATED GUIDELINES 2016 UPDATE

Policy brief: Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations, 2016 update. WHO/HIV/2017.05 World Health Organization 2017 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons. org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for noncommercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. Policy Brief: Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations, 2016 update. Geneva: World Health Organization; 2017 (WHO/HIV/2017.05). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris. Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/ bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing. Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user. General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use. Cover image UNAIDS/P. Virot Layout: L IV Com Sàrl, Villars-sous-Yens, Switzerland. Printed by the WHO Document Production Services, Geneva, Switzerland.

1 Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations The new consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations bring together all existing World Health Organization (WHO) guidance relevant to five key populations: men who have sex with men, people who inject drugs, people in prisons and other closed settings, sex workers and transgender people. It includes a number of new recommendations and updates existing guidance and recommendations. These guidelines aim to: 1 provide a comprehensive package of evidence-based HIV-related recommendations for key populations 2 increase awareness of the needs of and issues important to key populations 3 improve access to, uptake and coverage of effective and acceptable services and 4 catalyze greater national and global commitment to adequate funding and services. WHO/Marcus Garcia WHO CoE for Transgender Health WHO

Between 40% and 50% of all new HIV infections among adults worldwide occur among people from key populations and their immediate partners Estimates by the Joint United Nations Programme on HIV/AIDS (UNAIDS) suggest that as many as 50% of all new HIV infections worldwide occur in people from key populations. 1 In countries in Asia, Central Asia and Eastern Europe, people from key populations account for more than half of new infections from 53% to 62%. Even in the sub-saharan African countries with generalized epidemics that have carried out modes of transmission (MOT) analyses, the proportion of new infections in key populations is substantial, although it varies greatly for example, an estimated 10% in Uganda, 30% in Burkina Faso, 34% in Kenya, 37% in Nigeria, 43% in Ghana and 45% in Benin. In all countries and settings key populations are disproportionately affected by HIV. This disproportionate burden reflects both behaviour common among members of these populations and specific legal and social issues that increase their vulnerability. Yet HIV services for key populations remain largely inadequate. In many settings HIV incidence in key populations continues to increase, even as incidence stabilizes or declines in the general population. Country programmes and other end-users have indicated the importance of consolidating WHO s key population guidance to aid national programme managers and service providers, including those from community-based and community-led programmes, in planning and implementing services. To date, WHO has developed normative guidance separately for each of the five key populations, but in general that guidance has not fully addressed overarching issues common to all key populations. At the same time, other WHO global HIV guidance, including the 2013 Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection and the 2015 update, which focuses on people living with HIV, has not specifically considered issues relating to key populations. The consolidated key populations guidelines aim to address these gaps and limitations. The guidelines include a comprehensive package of interventions comprising the clinical interventions and critical enablers required for successful implementation of programmes for the five key populations. These guidelines also consider service delivery issues and provide guidance on decision-making, planning, and monitoring and evaluation. 1 UNAIDS 2013 unpublished Spectrum estimates.

Policy brief: Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations, 2017 3 THE COMPREHENSIVE PACKAGE a) Essential health sector interventions 1. comprehensive condom and lubricant programming 2. harm reduction interventions 1 for substance use (in particular needle and syringe programmes 2 and, opioid substitution therapy and naloxone distribution) 3. behavioural interventions 4. HIV testing and counselling 5. HIV treatment and care 6. prevention and management of co-infections and other co-morbidities, including viral hepatitis, tuberculosis and mental health conditions. 7. sexual and reproductive health interventions b) Essential strategies for an enabling environment 1. supportive legislation, policy and financial commitment, including decriminalization of certain behaviours of key populations 2. addressing stigma and discrimination, including by making health services available, accessible and acceptable 3. community empowerment 4. addressing violence against people from key populations. Recommendations The comprehensive package is based on the overarching recommendations described in detail in the document. These recommendations, which apply to both adults and adolescents, cover HIV prevention, diagnosis, treatment and comprehensive care across the continuum of care and provision of ART to prevent HIV transmission for people from key populations in serodiscordant relationships. Table 1 summarizes the recommendations. All recommendations and guidance in the document derive from existing WHO guidance with the exception of new recommendations on pre-exposure prophylaxis of HIV infection (PrEP) and opioid overdose management. Implications for programming Both public health and equity considerations underlie the need to prioritize and improve HIV services for key populations. These guidelines aim to support countries to provide more effective and acceptable comprehensive HIV services for key populations, to increase coverage and to address current inequities in access. Countries will need to assess their specific situations, taking into account current population sizes and reviewing current coverage levels and the quality of programmes. It will be important also to assess and, as country-specific circumstances make possible, to address social and legal barriers that may be impeding progress. Further research With partner organizations WHO is developing a comprehensive implementation science framework for HIV interventions and services, highlighting key research priorities, including those for key populations. 1 This package is essentially the same as the comprehensive package for HIV prevention, treatment and care for people who inject drugs (PWID) that has been widely endorsed at the highest political level. For PWID the harm reduction component of the package and in particular the implementation of needle and syringe programmes and opioid substitution therapy remains the first priority. 2 Needle and syringe programmes are important for people who inject drugs and also for transgender people who require sterile injecting equipment to safely inject hormones for gender affirmation. Also important to HIV prevention are tattooing, piercing and other forms of skin penetration, which are particularly relevant for people in prisons and other closed settings.

4 Policy brief: Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations, 2017 TABLE 1. SUMMARY OF WHO RECOMMENDATIONS CONCERNING KEY POPULATIONS HEALTH SECTOR INTERVENTIONS HIV prevention 1 The correct and consistent use of condoms with condom-compatible lubricants is recommended for all key populations to prevent sexual transmission of HIV and sexually transmitted infections (STIs). 2 Oral pre-exposure prophylaxis (PrEP) containing tenofovir disproxil fumerate (TDF) should be offered as an additional prevention choice for key populations at substantial risk of HIV infection as part of combination HIV prevention approaches. NEW RECOMMENDATION 3 Post-exposure prophylaxis (PEP) should be available to all eligible people from key populations on a voluntary basis after possible exposure to HIV. 4 Voluntary medical male circumcision (VMMC) is recommended as an additional important strategy for the prevention of heterosexually acquired HIV infection in men, particularly in settings with hyperendemic and generalized HIV epidemics and low prevalence of male circumcision. Harm reduction 5 All people from key populations who inject drugs should have access to sterile injecting equipment through needle and syringe programmes. 6 All people from key populations who are dependent on opioids should be offered and have access to opioid substitution therapy in keeping with WHO guidance. 7 All people from key populations with harmful alcohol or other substance use should have access to evidence-based interventions, including brief psychosocial interventions involving assessment, specific feedback and advice. 8 People likely to witness an opioid overdose should have access to naloxone and be instructed in its use for emergency management of suspected opioid overdose. NEW RECOMMENDATION HIV testing and counselling (HTC) 9 Voluntary HTC should be routinely offered to all key populations both in the community and in clinical settings. Community-based HIV testing and counselling for key populations, linked to prevention, care and treatment services, is recommended, in addition to provider-initiated testing and counselling. HIV treatment and care 10 Key populations living with HIV should have the same access to antiretroviral therapy (ART) and to ART management as other populations. 11 All pregnant women from key populations should have the same access to services for prevention of mother-tochild transmission of HIV (PMTCT) and follow the same recommendations as women in other populations.

Policy brief: Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations, 2017 5 Prevention and management of coinfections and co-morbidities 12 Key populations should have the same access to tuberculosis prevention, screening and treatment services as other populations at risk of or living with HIV. 13 Key populations should have the same access to hepatitis B and C prevention, screening and treatment services as other populations at risk of or living with HIV. 14 Routine screening and management of mental health disorders (depression and psychosocial stress) should be provided for people from key populations living with HIV in order to optimize health outcomes and improve their adherence to ART. Management can range from co-counselling for HIV and depression to appropriate medical therapies. Sexual and reproductive health 15 Screening, diagnosis and treatment of sexually transmitted infections should be offered routinely as part of comprehensive HIV prevention and care for key populations. 16 People from key populations, including those living with HIV, should be able to experience full, pleasurable sex lives and have access to a range of reproductive options. 17 Abortion laws and services should protect the health and human rights of all women, including those from key populations. 18 It is important to offer cervical cancer screening to all women from key populations, as indicated in the WHO 2013 cervical cancer screening guidelines. 19 It is important that all women from key populations have the same support and access to services related to conception and pregnancy care, as indicated by WHO guidelines, as women from other populations. CRITICAL ENABLERS 1 Laws, policies and practices should be reviewed and revised where necessary, and countries should work towards decriminalization of behaviours such as drug use/injecting, sex work, same-sex activity and non-conforming gender identity and toward elimination of the unjust application of civil law and regulations against people who use/inject drugs, sex workers, men who have sex with men and transgender people. 2 Countries should work towards implementing and enforcing antidiscrimination and protective laws, derived from human rights standards, to eliminate stigma, discrimination and violence against people from key populations. 3 Health services should be made available, accessible and acceptable to key populations, based on the principles of medical ethics, avoidance of stigma, non-discrimination and the right to health. 4 Programmes should work toward implementing a package of interventions to enhance community empowerment among key populations. 5 Violence against people from key populations should be prevented and addressed in partnership with key populationled organizations. All violence against people from key populations should be monitored and reported, and redress mechanisms should be established to provide justice.

For more information, contact: World Health Organization 20, avenue Appia 1211 Geneva 27 Switzerland E-mail: hiv-aids@who.int http://www.who.int/hiv/pub/guidelines/keypopulations/ WHO/HIV/2017.05